Filtered Listing Testing
Find information on treatment options for dry and wet age-related macular degeneration.
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Global brain and vision research nonprofit BrightFocus Foundation has appointed three industry leaders to its board of directors.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
